Europe TAVR Market

Europe TAVR Market Size (2022 to 2027)

The size of the European Transcatheter Aortic Valve Replacement Market is predicted to hit USD 1.73 billion by 2027 from USD 0.77 billion in 2022, growing at a CAGR of 17.40% between 2022 to 2027.

Transcatheter aortic valve replacement procedure has seen an increase in many European regions. TAVR is preferred as an effective valve replacement procedure over conventional open-heart surgery for the benefit of low-risk and high-risk patients and elderly patients over the age of 70. According to the World Health Organization (WHO), people with cardiovascular disorders will increase to 22.2 million by 2030 worldwide. In addition, growing studies have shown aortic valve catheter replacement (TAVR) for low risk of infection, loss of minimal blood, and less expensive than other surgical alternatives. These factors are estimated to drive the EU market during the forecast period.

Many European nations have seen an increase in cardiovascular diseases and surgeries, estimated to drive the European TAVR market. Between 2007-2015, a total of 131,500 procedures were performed in France, where 109,340 or almost 83.5% performed were surgical AVR (SAVR) and nearly 21,935 or 17%, TAVR were reported. From 2007-2015, There has been a sharp increase in the number of TAVR performed in France, owing to the high adoption of TAVR, amounting to a third of all aortic valve replacement surgeries performed in 2015. In Germany, 35,500 isolated heart valve procedures were performed, out of which nearly 17,475 were transcatheter procedures. These procedures suggested the positive outcome supported with numerous clinical trials with a recorded survival rate was 96.7%.

The increasing prevalence of cardiovascular diseases and the excellent healthcare infrastructure are some of the key factors responsible for driving the growth of the European TAVR market during the forecast period.

The high cost associated with the procedures and the lack of clinical success rate supported by recorded data is predicted to restrain the market growth. In addition, there are strict government regulations for the approval of transcatheter aortic valves, which are Class III medical devices, and limited patient bas over the age of 70 years are hampering market growth of the European TAVR market for the years to come.

This research report on the European TAVR Market has been segmented and sub-segmented into the following categories:

By Surgery Method:

• Transfemoral Implantation
• Transapical Implantation
• Transaortic Implantation
• Transvaal Implantation                  

By Valve Material:

• Nitinol
• Stainless Steel
• Cobalt-Chromium              

By Valve Size:

• 14mm to 18 mm
• 18mm to 22 mm
• 22mm to 29mm                    

By Valve Leaflets Material:

• Bovine Heart Tissue
• Cow Heart Tissue
• Other Valve Leaflets Material                       

By End Users:

• Hospitals
• Ambulatory Surgical Centres
• Cardiac Catheterization Laboratories     

By Country:

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

In Europe, countries such as France, Germany, the United Kingdom, and Italy are the main markets for TAVR, with a preference for aortic valve procedures and technological advancements in the regions. The European TAVR market will see Germany experiencing the highest growth rate of 9.8% during the forecast period (2022 - 2027) due to the increase in severe aortic stenosis cases, the growing elderly population, and favorable reimbursement policies. In Germany, all catheter valve implantation (TAVI) and aortic valve replacement (SAVR) procedures are registered under a mandatory quality assurance program managed by the Independent Institute for Improvement of Applied Quality and Health Care Research (AQUA). According to AQUA reports, the annual number of SAVR procedures increased from 11,252 in 2009 to 9,985 in 2015. In addition, the German Aortic Valve Registry (GARY), founded in 2010, records all the patients' data and co-relates all available treatment options and evaluates new treatment options compared with surgical AVR procedures. Over the period 2008-2014, the number of TAVR increased by 20 times, from 638 in 2008 to 13,265 in 2014.

Over the forecast period, France is anticipated to have a dominant share. The French regional market had a market share of 37.8% in the year 2019. The regional market is favored with the increasing incidence of aortic stenosis coupled with favorable reimbursement policies. Currently, physicians prefer alternatives over conventional techniques to reduce operational costs and reduce patient recovery time. Hence, the implementation of the TAVR technology in hospital care has increased rapidly in recent years.

KEY MARKET PLAYERS:

Companies playing a pivotal role in the European Transcatheter Aortic Valve Replacement (TAVR) Market profiled in this report are Edwards Lifesciences Corporation (U.S.), Medtronic, Inc. (Ireland), Boston Scientific Corporation (U.S.), Abbott Laboratories (U.S.), St. Jude Medical Inc. (U.S.), JenaValve Technology, Inc. (Germany), Symetis SA (Switzerland), Direct Flow Medical, Inc. (U.S.), Sorin Group (Italy), Meril Life Sciences India Pvt Ltd (India) and Braile Biomedica (Brazil).